Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Srne save search
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
covid-19 treatment trial
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.52%
H: 42.58%
C: 36.03%
osteoarthritis positive treatment trial therapeutics results
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
Published: 2023-07-05 (Crawled : 13:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 5.1%
H: 1.02%
C: -0.27%
positive treatment results study
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 3.9%
H: 0.0%
C: -3.06%
sti-1558 covid-19 treatment trial
Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain
Published: 2023-05-04 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8942 -23.57% -30.84% 2.8M
|
|
| O: 0.0%
H: 4.91%
C: -4.36%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -0.46%
H: 2.92%
C: -0.5%
sp-103 ztlido back treatment study
Sciatica Treatment Market to Reach USD 991.3 Million, Globally, by 2031 at 3.9% CAGR: Allied Market Research
Published: 2023-02-15 (Crawled : 16:00) - prnewswire.com
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: -0.98%
H: 1.58%
C: 1.58%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.27%
H: 2.75%
C: -17.4%
treatment research market
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Published: 2023-02-12 (Crawled : 00:00) - globenewswire.com
SCLX | $0.8942 -23.57% -30.84% 2.8M
|
|
| O: -20.92%
H: 10.39%
C: -6.84%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -35.61%
H: 9.04%
C: -57.51%
treatment canada migraine
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Published: 2022-11-29 (Crawled : 20:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.6%
H: 3.54%
C: 2.36%
sti-1558 covid-19 treatment australia topline china positive study
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Published: 2022-10-17 (Crawled : 13:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 4.48%
H: 11.43%
C: 9.29%
sti-1558 covid-19 treatment trials global study
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
Published: 2022-10-06 (Crawled : 13:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.24%
H: 3.46%
C: -1.89%
treatment lung therapeutics
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -0.65%
H: 5.19%
C: -1.95%
treatment osteoarthritis trial therapeutics phase 2
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute LBP
Published: 2022-08-31 (Crawled : 08:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation granted fast track designation
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Published: 2022-08-31 (Crawled : 04:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation back granted fast track designation
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Published: 2022-08-03 (Crawled : 13:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.77%
H: 8.32%
C: 2.3%
sti-1558 covid-19 treatment study
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Published: 2022-06-14 (Crawled : 15:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 2.16%
H: 1.41%
C: -0.7%
gloperba treatment license
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published: 2022-06-03 (Crawled : 15:20) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 8.18%
H: 2.33%
C: -0.58%
sti-1558 covid-19 treatment therapeutics
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Published: 2022-03-31 (Crawled : 14:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.27%
H: 0.26%
C: -2.92%
covid-19 treatment fda clearance phase 2
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
Published: 2021-12-07 (Crawled : 19:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.68%
H: 9.4%
C: 7.52%
treatment phase 2 xin osteoarthritis trial enroll
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
Published: 2021-12-05 (Crawled : 20:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -9.22%
H: 0.0%
C: 0.0%
treatment covid potential sars-cov-2 infections
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.